
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
RFLAT-1 CRISPR/Cas9 KO Plasmid (h) | sc-404618 | 20 µg | $397.00 |
KLF13 encodes the transcription factor RFLAT-1, a Krüppel-like zinc finger protein that binds GC-rich promoter elements to modulate gene expression programs controlling lymphocyte activation and inflammatory signaling. RFLAT-1 has been linked to regulation of chemokine and cytokine transcription and can interface with pathways such as NF-κB-dependent transcriptional responses, shaping immune-cell differentiation and activation states. Dysregulated KLF13/RFLAT-1 activity has been studied in contexts of immune-mediated pathology and altered inflammatory gene signatures, as well as in transcriptional networks that contribute to aberrant proliferation and survival in disease-relevant cell types. These properties make KLF13 a useful node for dissecting stimulus-responsive transcriptional regulation and immune gene circuitry in human model systems.
RFLAT-1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KLF13 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KLF13 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KLF13 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish RFLAT-1 protein expression.
This CRISPR knockout system enables efficient generation of KLF13-deficient cell models for investigation of RFLAT-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.